Cargando…

P1131: POST HOC ANALYSIS OF PATIENTS WITH HIGHLY PROLIFERATIVE VARIANTS OF MANTLE CELL LYMPHOMA TREATED WITH ACALABRUTINIB

Detalles Bibliográficos
Autores principales:	Le Gouill, S., Długosz-Danecka, M., Rule, S., Luigi Zinzani, P., Goy, A., Smith, S. D., Doorduijn, J. K., Panizo, C., Shah, B., Davies, A., Eek, R., Jacobsen, E., Kater, A. P., Robak, T., Jain, P., Calvo, R., Yang, H., Wang, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430145/ http://dx.doi.org/10.1097/01.HS9.0000847392.35657.0d

Ejemplares similares

Acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukaemia
Publicado: (2020)

Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy
por: Girard, Jennifer, et al.
Publicado: (2019)

P1094: SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL
por: Phillips, Tycel, et al.
Publicado: (2023)

P1130: ACALABRUTINIB IN TREATMENT-NAIVE OR RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: 5-YEAR FOLLOW-UP OF A PHASE 2, SINGLE-ARM STUDY
por: Owen, R., et al.
Publicado: (2022)

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
por: Byrd, John C., et al.
Publicado: (2021)

Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study
por: Strati, Paolo, et al.
Publicado: (2021)

Management of mantle cell lymphoma in the elderly patient
por: Doorduijn, Jeanette K, et al.
Publicado: (2013)

PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, T., et al.
Publicado: (2022)

Acalabrutinib: Disseminated aspergillosis: case report
Publicado: (2022)

M11.3.1: Requirements for electron beam diagnostics
por: Malka, V, et al.
Publicado: (2014)

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib
por: Bye, Alexander P., et al.
Publicado: (2022)

Run 1131 - 6th June 1980, Test of a procedure for the correction of the dipole defects in the superconducting insertion
por: Martucci, P, et al.
Publicado: (1980)

Proliferative glomerulonephritis and mantle cell lymphoma: a rare association
por: Mhedhbi, Bilel, et al.
Publicado: (2021)

The role of acalabrutinib in adults with chronic lymphocytic leukemia
por: Fakhri, Bita, et al.
Publicado: (2021)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

PB1948: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, Tatyana, et al.
Publicado: (2023)

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
por: Seymour, John F., et al.
Publicado: (2023)

Unexpected pathological findings after laparoscopic cholecystectomy – analysis of 1131 cases
por: Bartosiak, Katarzyna, et al.
Publicado: (2017)

Isolation, characterization and in vivo efficacy of Escherichia phage myPSH1131
por: Manohar, Prasanth, et al.
Publicado: (2018)

Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations
por: Wu, Chenglin, et al.
Publicado: (2016)

PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES
por: Shadman, M., et al.
Publicado: (2022)

WCN23-1131 RISK OF AKI IN COVID-19 PATIENTS: CLINICAL COURSE AND OUTCOMES
por: Flores Fonseca MD, M.M., et al.
Publicado: (2023)

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions
por: Series, Jennifer, et al.
Publicado: (2019)

Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective
por: Sood, Nitin, et al.
Publicado: (2021)

Acalabrutinib in Membranous Nephropathy Associated With Chronic Lymphocytic Leukemia
por: Izzedine, Hassan, et al.
Publicado: (2022)

Identification of urban land use efficiency by indicator-SDG 11.3.1
por: Cai, Guoyin, et al.
Publicado: (2020)

Reducing Bureaucracy in Clinical Research: A Call for Action
por: Gribben, John, et al.
Publicado: (2020)

APOAV (T-1131>C) variant has no effect on mother's height in a large population study
por: Hubacek, Jaroslav A, et al.
Publicado: (2004)

Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?
por: Haselager, Marco V., et al.
Publicado: (2020)

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia
por: Tucker, David L, et al.
Publicado: (2015)

Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma
por: Thus, Yvonne J., et al.
Publicado: (2022)

Phase II study of acalabrutinib in ibrutinibintolerant patients with relapsed/refractory chronic lymphocytic leukemia
por: Rogers, Kerry A., et al.
Publicado: (2021)

D11.3.1: Results from the operation of EMMA using the new diagnostics
por: Machida, S
Publicado: (2012)

1131. Prevalence and Characteristics of Non-β-Lactam Allergy Labeling at a Children’s Hospital
por: Miceli, Amanda, et al.
Publicado: (2019)

Interest of FDG-PET in the Management of Mantle Cell Lymphoma
por: Bailly, Clément, et al.
Publicado: (2019)

Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6
por: de Jong, Jan, et al.
Publicado: (2020)

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
por: Vitale, Candida, et al.
Publicado: (2021)

Abstract: One-Stage Augmentation Mastopexy: A Retrospective Ten-Year Review of 1,131 Consecutive Cases
por: Messa, Charles A., et al.
Publicado: (2017)

Association of Apolipoprotein A5 Gene −1131T>C Polymorphism with the Risk of Metabolic Syndrome in Korean Subjects
por: Song, Kwang Hoon, et al.
Publicado: (2013)

An Ultrafast UPLC–MS/MS Method for Characterizing the In Vitro Metabolic Stability of Acalabrutinib
por: Attwa, Mohamed W., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j3ak3ot71krt68nf6hq8te4tqn